Pfizer’s May Orfali Joins CANbridge as Chief Medical Officer

May Orfali has been appointed chief medical officer of CANbridge Life Sciences. She will replace Mark Goldberg, who was serving as interim chief medical officer. CANbridge, which is based in Beijing, China, and has additional sites in Shanghai and Cambridge, MA, takes Western drug candidates and develops them for the markets in China, Korea, and Taiwan. Orfali, who was most recently executive director of global product development at Pfizer (NYSE: [[ticker:PFE]]), will be based in Cambridge.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan